FY2025 EPS Estimates for Amarin Decreased by Zacks Research

Amarin Co. plc (NASDAQ:AMRN) – Stock analysts at Zacks Research decreased their FY2025 earnings per share estimates for Amarin in a research note issued on Tuesday, February 11th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of ($0.34) per share for the year, down from their prior estimate of ($0.33). The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.10) EPS.

Separately, StockNews.com upgraded Amarin from a “sell” rating to a “hold” rating in a research report on Tuesday.

Amarin Stock Performance

Shares of AMRN stock opened at $0.61 on Friday. Amarin has a fifty-two week low of $0.43 and a fifty-two week high of $1.36. The firm has a market capitalization of $251.49 million, a price-to-earnings ratio of -6.80 and a beta of 1.83. The stock’s 50-day simple moving average is $0.53 and its 200-day simple moving average is $0.57.

Institutional Investors Weigh In On Amarin

A number of large investors have recently bought and sold shares of AMRN. Arkfeld Wealth Strategies L.L.C. boosted its position in Amarin by 52.6% in the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 20,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Amarin in the fourth quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. lifted its holdings in Amarin by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 29,992 shares during the period. Generation Capital Management LLC acquired a new position in Amarin in the fourth quarter valued at approximately $50,000. Finally, Kornitzer Capital Management Inc. KS lifted its holdings in Amarin by 80.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 42,700 shares during the period. Hedge funds and other institutional investors own 22.25% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.